MediLink Therapeutics (Suzhou) Co., Ltd.

MediLink Therapeutics (Suzhou) Co., Ltd. is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies, founded on July 08, 2020. The company states that it focuses on developing internationally competitive drug conjugates and the latest generation of technologies and products with independent intellectual property rights and better therapeutic windows, to serve unmet clinical needs. Its management team was established by a senior ADC team covering the entire ADC process, and the company operates subsidiaries and offices in Shanghai, the United States, Hong Kong, Singapore and Suzhou.

MediLink Therapeutics was founded on July 08, 2020 as an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. The company states it was formed by experienced scientists from both small and large molecule drug development fields, and that its management team has collectively put over 20 new compounds into clinical developments, 3 of them antibody drug conjugates. Its management team was established by a senior ADC team covering the entire ADC process. The company's stated history includes: in December 2024, YL201 was granted Orphan-Drug Designation; in January 2025, a TMALIN® ADC technology platform license agreement with ZaiLab; in February 2025, YL217 was approved by FDA for clinical trials; in June 2025, YL201 was granted Breakthrough Therapy Designation by FDA; in July 2025, a CTO onboarding; in January 2026, YL201 collaboration with Roche; and in May 2026, YL201 met endpoints in the pre-specified Phase III NPC interim analysis.

Focus on the ADC field, promote technology iteration and product development, and establish technology and product advantages; develop internationally competitive drug conjugates to serve global patients.

• Tambotatug Pelitecan (Tam-Peli, YL201)

  An investigational B7-H3 targeted antibody-drug conjugate (ADC).

• YL217

  Approved by FDA for clinical trials in February 2025.

• YL413

  MediLink Therapeutics' first dual-payload ADC; FDA granted IND approval.

• 2021-03-01

  MediLink Therapeutics closes $50 million Series A financing[6]MediLink Therapeutics完成5000万美元A轮融资prnewswire.com

  Reported: 2021-03-01

  MediLink Therapeutics announced that it had closed a $50 million Series A financing, with a Series-A1 round led by Apricot Capital and a Series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.

1. 1Medilink Therapeuticsmedilinkthera.com
2. 2Medilink Therapeuticsmedilinkthera.com
3. 3Medilink Therapeuticsmedilinkthera.com
4. 4Medilink Therapeuticsmedilinkthera.com
5. 5MediLink Therapeutics (Suzhou) Co., Ltd. (China)wikidata.org
6. 6MediLink Therapeutics完成5000万美元A轮融资prnewswire.com